Dosage simulation
Dosage regimens were simulated based on eGFRCysC and MPO
stratification. AAV patients with elevated CysC should receive lower
dose of MPA while patients with elevated MPO should receive higher dose
of MPA (Supplemental Table 1). A dose of 750 mg (650
mg·m-2) twice daily was needed to achieve the target
AUC0-12h in AAV children with normal renal function and
no inflammation. Impaired renal function (eGFRCysC =15
mL/min/1.73m2) significantly impacted MPA CL, with
almost a 2/3 dose reduction than normal renal function
(eGFRCysC=90 mL/min/1.73m2). The
combined effects of MPO and renal function resulted in a 6-fold range in
MPA dose.